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_______________________________________________________________________________________ 
Background: Luminescent conjugated polymers 
(LCPs) are highly specific to amyloid 
conformations and may represent potential 
antiprion compounds. 
Results: LCPs significantly reduce prion titers, 
while rendering PrPSc more stable to proteolytic 
digestion. 
Conclusion: LCPs possess pronounced antiprion 
potential and appear to act by compaction of 
frangible fibers. 
Significance: LCPs may represent novel 
pharmacophores for the prevention and treatment 
of prion diseases. 
 
 
SUMMARY 
LCPs interact with ordered protein 
aggregates and sensitively detect amyloids of 
many different proteins, suggesting that they 
may possess antiprion properties. Here we 
show that a variety of anionic, cationic and 
zwitterionic LCPs reduced the infectivity of 
prion-containing brain homogenates and of 
prion-infected cerebellar organotypic cultured 
slices (COCS), and decreased the amount of 
PrPSc oligomers that could be captured in an 
avidity assay. Paradoxically, treatment 
enhanced the resistance of PrPSc to proteolysis, 
and triggered the compaction and enhanced 
the resistance to proteolysis of recombinant 
mPrP23-231 fibers. These results suggest that 
LCPs act as antiprion agents by transitioning 
PrP aggregates into structures with reduced 
frangibility. Moreover, ELISA on COCS and 
in vitro conversion assays with mPrP23-231 
indicated that PTAA may additionally 
interfere with the generation of PrPSc by 
stabilizing the conformation of PrPC or of a 
transition intermediate. Therefore, LCPs 
represent a novel class of antiprion agents 
whose mode of action appears to rely on 
hyperstabilization, rather than destabilization, 
of PrPSc deposits.     
________________________________________ 
Prion diseases are neurodegenerative, 
infectious disorders characterized by the 
deposition of β-sheet rich aggregates. These 
invariably fatal diseases can be inherited (1), arise 
spontaneously (2), or develop upon transmission 
of prion infectivity (3-5). The infectious agent is 
termed prion and is mainly composed of PrPSc, a 
partially protease-resistant isoform of the 
physiologically occurring prion protein PrPC (6). 
PrPSc condenses into macromolecular aggregates 
that accumulate within the CNS and to a lesser 
extent in other organs (6,7). The conversion of 
PrPC into PrPSc can be triggered by transmitting 
prions between organisms. Also, it is becoming 
increasingly evidence that many amyloid diseases 
progress through the trans-cellular propagation of 
prion-like seeds termed "prionoids" (8,9).  
No efficient treatments against prion diseases 
are available (10). The central role played by 
PrPSc in prion diseases has inspired searches for 
compounds influencing PrPSc stability and/or 
clearance. Inhibition of PrPSc conversion in prion-
infected cultured cells (11) or in animal models 
(12) was reported for molecules that can cross the 
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blood-brain barrier (BBB) such as amphotericin B 
(12), quinacrine, and chloropromazine. However, 
clinical trials in humans revealed no significant 
improvements of the course of chronic disease 
(13-15). 
Several polyanions can interfere with prion 
replication. Congo red (CR) (16) and the 
fluorescent antracycline iododoxorubicin (17) 
prolong incubation time in rodents upon co-
inoculation with prions. CR interacts with, and 
stabilizes, PrPSc (18), whereas iododoxorubicin 
binds to PrPSc deposits in brain sections of CJD 
patients (17). It is therefore likely that the 
interaction of such compounds with infectious 
prion species is responsible for a decrease of prion 
infectivity. Therefore, compounds that stabilize 
prions could represent valuable tools for the 
treatment or the prophylaxis of prion diseases. 
The structural requirements for the antiprion 
activity of sulphated polyanions in chronically 
infected cells were investigated in detail (19). 
These compounds are believed to interfere with 
the interaction of endogenous glycosaminoglycans 
with PrPC and/or PrPSc rather than acting directly 
onto PrPSc aggregates. The most promising 
compound, pentosan polysulfate (PPS) (20,21) is 
currently undergoing clinical trials despite its poor 
pharmacokinetics and high toxicity (22). Finally, 
complex polyamines have been shown to 
disaggregate PrP but suffer poor bioavailability 
(23). Therefore it would be desirable to identify 
new classes of compounds with drug-like 
properties (including high bioavailability and low 
toxicity) that directly influence amyloid 
propagation. 
Luminescent conjugated polythiophenes 
(LCPs) are versatile probes with striking affinity 
to variety of amyloids (24-27). Upon binding 
amyloids, LCPs adopt distinct conformations with 
characteristic spectral properties (28) specific to 
distinct amlyoid types (27). Newer-generation 
LCPs efficiently cross the blood-brain barrier, 
enabling visualization of protein aggregates in 
vivo and, potentially, clinical trials. 
Here we investigate the potential of various 
LCPs as novel antiprion compounds. All tested 
LCPs significantly reduced prion infectivity while 
increasing the protease resistance of PrPSc. We 
therefore posit that the polythiophene scaffold is a 
novel, generic amyloid-stabilizing pharmacophore 
which could spawn useful antiprion compounds. 
EXPERIMENTAL PROCEDURE 
General methods of the synthesis of PBAT 
− Organic extracts were dried over anhydrous 
magnesium sulfate, filtered and concentrated in 
vacuo at 40 °C. All chemicals were purchased 
from Sigma-Aldrich Co (Sigma-Aldrich, St. 
Louis, MO, USA) and used as is. NMR spectra 
were recorded on a Varian 80 instrument (1H 300 
MHz, 13C 75.4 MHz, Varian Inc., Santa Clara, 
CA, USA). Chemical shifts were assigned with 
the solvent residual peak as a reference according 
to Gottlieb et al.(76). Thin layer chromatography 
(TLC) was carried out on Merck precoated 60 
F254 plates (Merck, Whitehouse Station, NJ, 
USA) 85 using UV light (l = 254 nm and 366 nm) 
and charring with ethanol/sulfuric acid/p-
anisaldehyde/acetic acid 90:3:2:1 for 
visualization. Flash column chromatography (FC) 
was performed using silica gel 60 (0.040–0.063 
mm, Merck). Gradient HPLC-MS was performed 
on a Gilson system (Gilson, Middleton, WY, 90 
USA). Column: Waters X-Bridge C-18 5 µm, 250 
x 15 mm and Waters X-Bridge C-18 2.5 µm, 150 
x 4.6 mm for semipreparative and analytical runs 
respectively; using acetonitrile with 0.05% formic 
acid and deionized water with 0.05% formic acid 
as mobile phase. MALDI-TOFMS was recorded 
in linear positive mode with the analyte as matrix. 
Normal work up means that the organic extracts 
were dried on MgSO4, filtered and concentrated in 
vacuo. 
Synthesis of 2-(3-thienyl)-p-toluenesulfonyl 
ethanol (2) −  2-(Thiophene-3-yl) ethanol (0.700 
g, 5.43 mmol) was added to a solution of CHCl3 
and pyridine (1:1, 12.0 ml). p-toluensulfonyl 
chloride (1.24 g, 6.50 mmol) was added. After 16 
h reaction was quenched by adding water (20 ml) 
and ether (100 ml). The organic layer was washed 
with HCl (1 M aq, 4 x 25 ml) and water (3 x 25 
ml) and subjected to normal workup. The product 
was purified by FC (toluene) to give (2) (1.47 g, 
97 %) as pale yellow oil. TLC (toluene) Rf=0.09 
1H-NMR (CDCl3) δ: 2.44 (s, 3H), 2.99 (t, 2H, 
J=6.9), 4.21 (t, 2H, J=6.9), 6.87 (dd, 1H, J=1.5, 
5.1 Hz), 6.97 (m, 1H), 7.23 (dd, 1H, J=3.0, 5.1 
Hz), 7.31 (d, 2H, J=8.4 Hz), 7.73 (d, 2H, J=8.4 
Hz). 
13C-NMR (CDCl3) δ: 21.6, 29.8, 69.9, 122.1, 
125.8, 127.8, 128.0, 129.8, 133.3, 135.9, 144.9. 
Synthesis of (S)-3-[2-(3-thienyl)-ethoxy]-2-
tert-butoxycarbonylamino-propionic acid (3) −  
(2) (1.23 g, 4.36 mmol) was dissolved in dry DMF 
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(45 mL), N-Boc-L-Ser-OH (1.79 g, 8.72 mmol) 
and K2CO3 (1.81 g, 13.1 mmol) were added to the 
solution. The mixture was heated to 45 °C and the 
reaction was quenched after 24 h by pouring the 
mixture over ice and HCl (2 M aq). The product 
was extracted with toluene (3 x 40 ml), which was 
subsequently washed with HCl (2 M aq, 2 x 25 
ml) and NaCl (sat. aq, 3 x 50 ml), followed by 
normal workup. The syrup was purified by FC 
(toluene -> toluene/ethyl acetate, 4:1) and gave 
the colorless syrup product (3) (0.879 g, 64 %). 
TLC (toluen/ethyl acetate, 4:1) Rf=0.1 
1H-NMR (CDCl3) δ: 1.43 (s, 9H), 2.86 (s, 
1H), 2.98 (t, 2H, J=6.9), 3.84 (dd, 1H, J=3.5, 11.3 
Hz), 3.85 (dd, 1H, J=3.8, 11.3 Hz), 4.42 (m, 3H), 
5.51 (d, 1H, J=7.8 Hz), 6.95 (dd, 1H, J=1.5, 4.6 
Hz), 7.03 (dd, 1H, J=1.5, 2.9 Hz), 7.25 (dd, 1H, 
J=2.9, 4.6 Hz) 
13C-NMR (CDCl3) δ: 28.2, 29.4, 55.7, 63.3, 
65.2, 80.2, 121.7, 125.7, 128.1, 137.5, 155.7, 
170.7 
Synthesis of (R)-1-carboxy-N,N,N-trimethyl-2-
(2-(thiophen-3-yl)ethoxy)ethanaminium (4) −  (3) 
(0.692 g, 2.10 mmol), NaHCO3 (0.706 g, 8.41 
mmol) and methyl iodide (2.09 ml, 33.6 mmol) 
were dissolved in dry DMF (35 ml). After three 
days the reaction was diluted with toluene (100 
ml) and co-evaporated to give a yellow solid. The 
precipitate was dissolved in methanol (50 ml) and 
washed with heptane (2 x 30 ml). The mixture 
was concentrated and the product was purified by 
HPLC [ACN/H2O, 5:95 14 min; flow: 7 mL/min; 
wavelength: 210 nm; Mass: 257.12 (calculated 
and found)] to afford (4) (0.565 g, 70 %) as pale 
yellow crystals. 
1H-NMR (Methanol-d4) δ: 3.07 (t, 2H, J=6.6 
Hz), 3.31 (s, 9H),  
4.16 (dd, 1H, J=5.4, 13.5 Hz), 4.23 (dd, 1H, 
J=3.3, 13.5 Hz), 4.39 (dd, 1H, J=3.3, 5.4 Hz), 
4.48 (dt, 1H, J=6.6, 10.8 Hz), 4.56 (dt, 1H, J=6.6, 
10.8 Hz), 7.05 (dd, 1H, J=1.5, 4.8 Hz), 7.20 (dd, 
1H, J=1.5, 2.7 Hz), 7.36 (dd, 1H, J=2.7, 4.8 Hz) 
13C-NMR (Methanol-d4) δ: 30.2, 54.3, 59.4, 
67.6, 76.1, 123.1, 126.9, 129.2, 139.0, 166.8 
Synthesis of Poly-((R)-1-carboxy-N,N,N-
trimethyl-2-(2-(thiophen-3-
yl)ethoxy)ethanaminium) (5) −  (4) (0.172 g, 0.666 
mmol), FeCl3 (0.486 g, 3.00 mmol) and 
tetrabutylammonium-trifluoromethanesulfonate 
(0.521 g, 1.33 mmol) was added to a solution of 
dry chloroform (13.5 ml). After 2 h the mixture 
was quenched by adding water (3 ml). The 
organic layer was extracted by water (2 x 3 ml). 
The aqueous solution was made acidic by HCl 
(conc. aq) and acetone was added to the mixture 
until the polymer precipitated as red flakes. The 
mixture was centrifuged and the yellow water was 
decantated. The procedure was repeated until the 
yellow color, from dissolved FeCl3, of the water 
had disappeared. The polymer was dissolved in 
water and lyophilized, resulting in a red powder 
(5) (0.0722 g, 37 % calculated with respect to the 
monomeric unit). 
Preparation of LCP stock solutions − The 
synthesis of the other different LCPs has been 
described elsewhere (24,26,29-35,77). 
Lyophilized LCPs were resuspended in pure water 
(B. Braun, Melsungen AG) and stock solutions at 
a concentration of 1 mg ml–1 were prepared and 
stored at 4°C, protected from light. Serial 
dilutions of the LCPs were prepared in pure water. 
Preparation of CD1 and RML6 crude brain 
homogenates and exposure to LCPs and PPS 
− 20% wt/vol CD1 or RML6 brain homogenates 
in 0.32 M sucrose in PBS were prepared by three 
runs in a Precellys24 tissue homogenizer (Bertin) 
with cooling on ice between each run. Protein 
concentrations of CD1 or RML6 brain 
homogenates were determined using the 
bicinchoninic acid assay (Pierce) and normalized 
to 1 mg ml–1 total protein with 0.32 M sucrose in 
PBS. 
LCPs and PPS were diluted into aliquots of 
crude brain homogenates at final concentrations 
ranging from 10-4 to 5000 µg ml–1 and to final 
volumes of 45 µl. All samples were incubated for 
30 min at 37°C on a thermoshaker rotating at 700 
rpm prior to proteolysis. 
Treatment of slice cultures with LCPs 
− Cerebellar slice cultures were prepared and 
prion-infected according to a protocol described 
by Falsig et al. (43,44). Slice culture medium was 
changed three times per week and 10 µl of diluted 
PTAA or PPS (30 µg ml-1, Bene pharmachem) 
was added to 1 ml medium to obtain final 
concentrations ranging from 0.01 to 60 µg ml-1 
PTAA or 0.3 µg ml-1 PPS. Treatment was initiated 
three weeks post-infection or in a time-course 
manner and maintained until tissue was harvested. 
Tissue was harvested in PBS and homogenized 
according to a protocol described by Falsig et al. 
(43,44). Protein concentration was determined 
using the bicinchoninic acid assay (Pierce) and 
normalized to 1 mg ml–1 total protein with PBS. 
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Western blot analysis − PrPSc was detected by 
limited proteolysis with PK (Roche) and analysed 
by Western blotting. Samples of 45 µl brain 
homogenate or 20 µl aliquots from slice culture 
homogenates containing 20 µg protein were 
digested with 50 µg ml-1 PK and 25 µg ml-1 PK, 
respectively, in lysis buffer containing 0.5% 
wt/vol sodium deoxycholate, 0.5% vol/vol 
Nonidet P-40 and 10% vol/vol PBS for 60 min at 
37°C and rotating at 700 rpm on a thermoshaker. 
PK digestion was terminated by adding 17 µl 
of 4x LDS loading buffer (NuPAGE, Invitrogen) 
and boiling the samples at 95 °C for 5 min. 30 µl 
of the samples were separated on a 12% Bis-Tris 
SDS polyacrylamide gel (NuPAGE, Invitrogen) 
and blotted onto a nitrocellulose membrane. 
Membranes were blocked with 5% wt/vol 
Topblock (Fluka) in Tris-buffered saline 
supplemented with Tween (150 mM NaCl, 10 
mM Tris HCl, 0.05% Tween 20 (vol/vol)) and 
incubated with POM1 mouse IgG1 antibody to 
PrPC (anti-PrPC) (200 ng ml-1) as primary 
antibody. Horseradish peroxidase (HRP)-
conjugated rabbit anti–mouse IgG1 (1:10,000, 
Zymed) was used as a secondary antibody. The 
blots were developed using SuperSignal West 
Pico chemiluminescent substrate (Pierce) and 
detected in a LAS3000 system (FUJI). 
Scrapie Cell End-Point Assay − SCEPA was 
performed as described previously (36). Briefly, 
RML6 samples consisting of 1% brain 
homogenate containing various concentrations of 
LCPs were diluted 1 to 100 fold in cell culture 
medium to obtain a final dilution of 10-4. These 
samples were then serially diluted in cell culture 
medium containing a 10-4 dilution of CD1 brain 
homogenate and dilutions of RML ranging from 
10-4 to 10-8 in 96-well plates. Each experimental 
run comprised four plates with the first plate 
containing a 10-4 to 10-8 decadal dilution of 
untreated RML6 as a control. The other three 
plates were used to analyze the titer of three 
dilutions of one LCP, or of three distinct LCPs.  
For slice culture homogenates, samples 
normalized to 1 mg ml–1 total protein were diluted 
1 to 100 fold in cell culture medium to obtain a 
final dilution of 10-4. These samples were then 
serially diluted in cell culture medium containing 
a 10-4 dilution of CD1 brain homogenate and 
dilutions of homogenates from COCS ranging 
from 10-4 to 10-8 and tested in 96-well plates. 
Experimental runs comprised four plates 
including a homogenate of COCS from six weeks-
old prion-infected, non-treated tissue as a standard 
plate. The infection of N2a-PK1 cells and 
subsequent processing of the SCEPA were 
performed as previously described (36). 
Misfolded protein assay − Samples of 10 µg 
total protein (brain homogenate prepared as 1% 
w/v in 0.32 M sucrose in PBS and normalized to 1 
mg ml–1) from LCP-treated RML6 or 5 µg total 
protein from slice culture homogenates were 
diluted 100 fold in TBSTT (50 mM Tris-HCl (pH 
7.5)/137 mM NaCl/1% Tween 20/1% Triton X-
100) and incubated for 10 min at 37 °C under 
permanent agitation (850 rpm). 100 µl was then 
subjected to precipitation using magnetic beads 
coupled to the peptoid PSR1 (37) for 1 h at 37 °C 
under permanent agitation (750 rpm). Beads were 
washed and trypsin digestion was performed (12.5 
µg ml–1 trypsin in TBST containing 5 mM CaCl2) 
for 30 min at 37 °C under permanent agitation 
(750 rpm) and stopped with 2 mM PMSF for 15 
min at RT. Beads were washed and denatured 
with 0.1 N NaOH. After neutralization (0.3 M 
Na2H2PO4), samples were placed on a magnet, 
and the supernatant was transferred to POM19 
(40)-coated ELISA plates. After incubation (1 h at 
37°C, 300 rpm), plates were washed, and AP-
conjugated POM2 (40) was added. After 
incubation with substrate (100 µl of Lumiphos 
Plus substrate (Lumigen, Southfield, MI), plates 
were read in a luminometry reader (Luminoskan 
Ascent; Thermo Fisher Scientific). 
Bead-based capture of PrPSc −  21 µl of 
PSR1-conjugated beads (37) were washed five 
times in 1 ml PBS (8 mM Na2HPO4, 1.5 mM 
KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH7.4) 
before incubation with different dilutions of a 
10% RML6 brain homogenate ranging from 10-2 
to 10-10 overnight at 4°C upon shaking at 1000 
rpm.  
Unbound material was removed from the 
beads by washing five times with 1 ml of PBS. 
The beads were resuspended in 60 µl or 120 µl in 
PBS and 30 µl, respectively, of the resuspended 
beads were intracerebrally inoculated into tga20 
mice with groups of at least 4 mice. 
Mice were monitored every second day, and 
TSE was diagnosed according to clinical criteria 
including ataxia, wobbling, and hind leg paresis. 
At the onset of terminal disease tga20 mice were 
sacrificed. Mice were maintained under 
conventional conditions, and all experiments were 
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performed in accordance with the animal welfare 
guidelines of the Kanton of Zürich. 
Histopathology and immunohistochemical 
stains − Two-µm thick sections were cut onto 
positively charged silanized glass slides and 
stained with hematoxylin and eosin, or 
immunostained using antibodies for PrP (SAF84), 
for astrocytes (GFAP). For PrP staining, sections 
were deparaffinized and incubated for 6 min in 
98% formic acid, then washed in distilled water 
for 5 min. 
Sections were heat-treated and 
immunohistochemically stained on an automated 
NEXES immunohistochemistry staining apparatus 
(Ventana Medical Systems, Switzerland) using an 
IVIEW DAB Detection Kit (Ventana). After 
incubation with protease 2 (Ventana) for 16 min, 
sections were incubated with anti-PrP SAF-84 
(SPI bio; 1:200) for 32 min. Sections were 
counterstained with hematoxylin. GFAP 
immunohistochemistry for astrocytes (rabbit anti–
mouse GFAP polyclonal antibody 1:1000 for 24 
min; DAKO) was similarly performed, however 
with antigen retrieval by heating to 100 °C in 
EDTA buffer (pH = 8.0).  
For western blot analysis, 10% brain 
homogenates were prepared in 0.32 M sucrose 
using a Precellys24 (Bertin). Extracts of 50-90 µg 
protein were digested with 50 µg/ml proteinase-K 
(PK) in DOC/NP-40 0.5% for 45 minutes at 37 
°C. The reaction was stopped by adding 3 µl 
complete protease inhibitor cocktail and 8 µl of a 
lauryl dodecyl sulfate (LDS)-based sample buffer.  
MTS assay − The MTS assay (PROMEGA) 
was performed according to the instructions given 
by the manufacturer. 
Conformational stability assays − Two 
aliquots of RML6 brain homogenate were 
normalized to 2 mg ml–1 protein and PTAA was 
added to obtain final concentrations of 0, 10 or 
100 µg ml–1 before the samples were incubated for 
30 min at 37°C on a thermoshaker rotating at 700 
rpm. Aliquots of 10 µl containing 20 µg protein 
each were prepared and two times diluted with 
either water or different concentrations of 
GdnHCl. The samples were incubated for 10 min 
at room temperature prior to analysis by Western 
blot or MPA. For Western blot analysis, the 
samples were digested with PK (15 µg/ml) and 20 
µl of the samples were separated on a 12% Bis-
Tris SDS polyacrylamide gel (NuPAGE, 
Invitrogen) followed by blotting onto a 
nitrocellulose membrane. For MPA analysis, 
samples without or with 10 µg ml–1 PTAA were 
diluted 1:100 in TBSTT prior to the capture with 
peptoid-coated beads and MPA was performed as 
described above. 
ELISA − Homogenates from COCS were 
diluted ten-fold in TBSTT to obtain a final 
concentration of 0.1 mg ml–1 total protein. 
Digestion with PK was performed in a 96-well 
plate for 60 min at 37°C, rotating at 700 rpm on a 
thermoshaker in a total volume of 50 µl 
containing 50 µg ml-1 PK. Digestion was stopped 
by adding 2 mM phenylmethanesulfonylfluoride 
(PMSF, Calbiochem) and Complete Mini protease 
inhibitor cocktail (Roche). Digested samples were 
denatured with an equal volume of 3 M GdnSCN 
for 30 min at 37°C and diluted with four volumes 
of 0.1 M NaHCO3, pH 8.9. The samples were then 
detected by sandwich ELISA. Briefly, ELISA 
plates were coated with POM1-antibodies (400 
ng/well) in coating buffer over night. After 
washing with PBST, plates were blocked with 
blocking buffer (5% TopBloc in PBST) for 2 h at 
room temperature. Next, samples were incubated 
for 2 hours on ELISA plates (Nunc, MaxiSorb). 
Captured samples were detected with biotinylated 
POM19 antibody (1 µg ml–1, 1 h, diluted in 
sample buffer) and horseradish peroxidase (HRP)-
avidin conjugate (1 µg ml–1, 1 h, diluted in sample 
buffer) (BD Pharmingen). Samples were analysed 
by ELISA in technical triplicates and washed five 
times with PBS 0.05% Tween20 between each 
antibody and conjugate incubations. The 
development was performed either 
calorimetrically or by chemiluminescence. For the 
calorimetric detection, TMB substrate 
(Invitrogen) was added to the wells and incubated 
for 15 min at room temperature and stopped by 
adding 0.5 M H2SO4. The absorbance was read at 
450 nm by VERSAmax microplate reader and 
validated with SOFTmax PRO software. For 
chemiluminescence, the chemiluminescent 
substrate (Thermo Scientific) was added to the 
wells and incubated for 3 min at room 
temperature. The relative light units were 
measured with a luminometer (~425nm) and 
validated with SOFTmax PRO software. 
Preparation of recombinant mouse mPrP23-
231 and fibril formation − Recombinant mouse 
PrP comprising residues 23-231 was expressed 
and purified as described elsewhere (78-80). 
mPrP23-231 fibers were produced by incubating the 
protein in 50 µM Tris-HCl, 1 M GdnHCl, 150 
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mM sodium chloride, pH 7.5, for 48 at 37 ºC h 
and shaking at 600 rpm (45). To study the 
inhibition of fiber formation by PTAA, mPrP23-231 
fibers were grown in the absence and presence of 
different concentrations of PTAA ranging from 1 
to 50 µg ml–1. The time course of fiber formation 
was followed by measuring the optical density at 
350 nm on a Tecan Saphire 2 plate reader. After 
48h the samples were also analysed by 
transmission electron microscopy. Preformed 
fibrils were mixed with PTAA at concentrations 
of 10, 25, 50 and 100 µg ml–1PTAA for 30 min at 
37°C and shaking at 600 rpm prior to analysis by 
transmission electron microscopy. 
Transmission electron microscopy − Carbon 
coated copper grids were placed on 10 µl of the 
fibril solutions and incubated for 1 min. After 
removing of excess liquid, grids were washed 
three times with water prior to staining with 2% 
aqueous uranyl acetate for 1 min. Samples were 
analysed on a Philips CM12 electron microscope 
(transmission electron microscope with an 
acceleration voltage of 80 keV. 
Proteolysis of mPrP23-231 fibers in the 
presence of PTAA − mPrP23-231 fibers were 
incubated in the absence and presence of 10 µg 
ml–1 PTAA at 37°C for 60 min on a thermoshaker 
rotating at 700 rpm. 18 µl of non-treated and 
PTAA treated fibers were digested with PK at 
concentrations of 0.5, 1, 1.5 and 2 µg ml−1 diluted 
in PBS for 60 min at 37°C on a thermoshaker 
rotating at 700 rpm. PK digestion was terminated 
by adding 7 µl of 4x LDS loading buffer 
(NuPAGE, Invitrogen) and boiling the samples at 
95 °C for 5 min. Samples were than analysed by 
immunoblotting.  
Histagged mPrP23-231 purification and fibril 
formation for the fluorescence assay −  Histagged 
mPrP23-231 was purified by affinity 
chromatography and size exclusion 
chromatography as described previously (81). 
Fibrils were generated by unfolding the protein in 
6 M GdnHCl followed by partial refolding by 
dilution to 1 M GdnHCl and 3 M urea and 5 µM 
mPrP23-231 at pH 7.3. The protein samples were 
shaken vigorously at 37 ºC for 24 h. 
Native and fibrillated mPrP23-231 was serially 
two-fold diluted in several steps in a 96 well plate 
(Corning 3880) and PTAA was added to a final 
concentration of 0.2 µM. The samples were 
excited at 430 nm and emission spectra were 
recorded from 470 and 600 using a Safire II plate 
reader (Tecan). Fluorescence polarization was 
determined by excitation at 470 nm and 
measuring the emission at 520 nm. The anisotropy 
was calculated as r = (I║- I└)/(I║+ 2I└) where r is 
the anisotropy, I║ is the parallel intensity and I└ is 
the perpendicular intensity.  
Statistical analysis −  For MPA presented in 
Figs 2, 4 and S11, technical quadruplicates were 
compared for each individual sample using a T-
test. In Fig. 2A, the overall effect of individual 
LCPs was investigated by comparing a group of 
four concentrations of each individual 
polythiophenes using a post-Hoc T-test for 
analysis of variance. 
For the SCEPA presented in Figs 2 and 4 and 
supplemental Fig. S7, proportion of negative wells 
over dilutions were compared between drugs 
using a Mantel-Haenszel Chi-square test with a 
Bonferroni-Holm correction. Confidence interval 
for common odds ratio is given in the respective 
tables for non-significant comparisons.  
For Fig. 4B, P-values were calculated with a 
one-sample T-test comparing TCI50 difference to 
control (homogenates from COCS of non-treated 
cultures harvested after 42 dpi). For Fig. 4C 
statistical differences were computed to compare 
each set of biological replica to the control 
homogenates from COCS with a one-way 
ANOVA.  
 
RESULTS 
LCPs stabilize PrPSc against proteolysis. In a 
first set of experiments, we screened a broad 
range of LCPs with various side chains and/or 
polymer length for their effects onto the stability 
of PrPSc to hydrolysis by PK. The compounds 
tested included polydisperse LCPs such as the 
anionic PTAA (24,26,29,30), the cationic POMT 
(26,29,30) and PTMI (31), the zwitterionic PBAT 
(supplemental Fig. S1) and POWT (30,32,33). We 
then tested monodisperse LCPs such as the 
anionic compounds pHTAA and pFTAA (34,35) 
(Fig. 1A). All LCPs are charged at physiological 
pH.  
We mixed a 1% brain homogenate obtained 
from mice infected with RML6 prions (Rocky 
Mountain Laboratory strain, passage 6) with each 
LCP (1-900 µg ml-1). Samples were incubated for 
30 min at 37°C in an orbital shaker (700 rpm). 
Samples were then digested with 50 µg ml-1 PK 
and analyzed by immunoblotting. Treatment with 
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each LCP (except tPOWT) was found to increase 
the PK resistance of PrPSc in a concentration-
dependent manner and to induce the formation of 
SDS-stable aggregates (Fig. 1B). PBAT and 
POWT were less effective at enhancing the PK 
resistance of PrPSc, but augmented the formation 
of oligomeric SDS-stable PrPSc aggregates. 
Longer exposures of the blots revealed that these 
aggregates were enhanced by all LCPs (Fig. 1B 
and supplemental Fig. S2). We also used PPS as 
control. PPS did not show any effect on PK 
resistance up to a concentration of 10 µg ml-1, 
whereas the LCPs had a strong effect at the same 
concentration (supplemental Fig. S3). 
To investigate the limit of the LCP-induced 
enhancement of PK resistance, we performed a 
digestion with a 40-fold higher concentration of 
PK on PTAA-treated RML6 and doubled the 
incubation time of proteolysis. The signal for 
untreated PrPSc was completely abolished, yet 
PTAA-treated PrPSc remained detectable even 
under these harsh conditions (supplemental Fig. 
S4). Exposure of RML6 to extremely high PTAA 
and POMT concentrations (>50 µg ml-1) reduced 
the levels of PrPSc (Fig. 1B and Fig. 4A). Hence, 
PTAA and POMT in extremely high 
concentrations may partially destabilize the 
protein aggregates.  
We performed several experiments to assess 
whether the presence of the LCPs compromised 
the assay used for assessing PK resistance, 
thereby leading to artifactual results. To 
investigate whether LCPs interfere with the 
enzymatic activity of PK, we PK-digested non-
infectious CD1 brain homogenates in the absence 
or presence of PTAA. We did not observe any 
effect of PTAA onto the efficiency of PrPC 
proteolysis (supplemental Fig. S5A and B). Next, 
we tested whether the addition of PTAA to PK-
predigested RML6 homogenate affects the level 
of PrPSc. The PrPSc signal increased only when 
proteolysis of RML6 prions was performed after 
exposure with PTAA, but not when PTAA was 
added a posteriori (supplemental Fig. S6). We 
conclude that LCPs indeed increase the resistance 
of PrPSc to PK by directly modifying the 
properties of PrPSc.  
LCPs reduce prion infectivity in brain 
homogenates − We then asked whether LCPs can 
reduce prion infectivity titers. We mixed 1% brain 
homogenate obtained from mice infected with 
RML6 prions with LCPs (300 µg ml-1) for 30 min 
at 37°C. Prion infectivity was then quantified by 
assessing TCI50 g-1 (number of units transmitting 
infectivity to tissue cultures with 50% likelihood 
per gram of brain homogenate) with the Scrapie 
Cell End-Point Assay (SCEPA) (36). All LCPs 
significantly reduced infectivity in RML6 
homogenates against non-treated RML6 
homogenate (log TCI50 g-1 >7.9 ± 0.3; Fig. 2A and 
supplemental Table S1). Due to their high 
activity, PTAA and its monodisperse counterpart 
pFTAA were further investigated in a titration 
assay. PTAA reduced infectivity in RML6 brain 
homogenates by 3 logs TCI50 g-1 at 900 µg ml-1, 
and completely abated infectivity at 5000 µg/ml. 
The effect of pFTAA on prion infectivity 
appeared similar to that of PTAA (Fig. 2B and C).  
The validity of the SCEPA is unaffected by 
LCPs. Next, we asked whether residual LCPs may 
affect the susceptibility of N2a-PK1 cells to 
prions, thereby producing artifactually optimistic 
results. In a first experiment a 10-fold excess of 
RML6 homogenate was added to RML6 samples 
treated, or non-treated, with 500 µg ml-1 PTAA 
(supplemental Fig. S7). The resulting prion titers 
were similar to those of non-treated RML6 
homogenates, whereas the PTAA-treated control 
sample exhibited decreased titers (supplemental 
Tables S2). Hence PTAA did not decrease the 
susceptibility of N2a-PK1 cells to prion infection, 
or the readout of the SCEPA. In a second 
experiment we tested whether preincubation of 
N2a-PK1 cells with PTAA would affect the 
susceptibility of cells to prion infection 
(supplemental Fig. S7). We supplemented the 
culture medium before infection with 10 µg ml-1 
PTAA, which corresponds to the PTAA 
concentration in the medium used for the RML6 
infection treated with 900 µg ml-1 (Fig. 2B). Prion 
titration by SCEPA yielded comparable TCI50 g-1 
values (supplemental Tables S3), confirming that 
the susceptibility of the cells to prion infection 
was not affected by the treatment with PTAA. We 
conclude that the PTAA-treated cells remained 
fully susceptible to RML6. Hence the observed 
decrease in infectivity in PTAA-treated sample 
represented a true PTAA-induced reduction of 
prion infectivity. 
Finally, cell viability was tested to exclude the 
possibility of acute toxicity of PTAA to N2a-PK1 
cells when supplemented into the culture medium 
(supplemental Fig. S8). PTAA at the highest dose 
of 45 µg ml-1 used in our study did not affect cell 
viability. Therefore LCP can suppress prion 
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infectivity of brain homogenates below the 
SCEPA detection limit without affecting the 
sensitivity of the assay.  
LCPs decrease the concentration of PrP 
aggregates − Because PK resistance is often used 
as a surrogate marker of prion infectivity, the 
finding that LCPs reduce infectivity while 
rendering PrPSc more resistant to PK digestion 
was counterintuitive. We therefore used the 
Misfolded Protein Assay (MPA) to further 
analyze the physical properties of LCP-treated 
prions. The MPA enables sensitive and 
quantitative detection of prion aggregates without 
the use of PK (37-39). Paramagnetic beads coated 
with prion-specific binding peptoids selectively 
capture PrP aggregates, whereas monomeric PrP 
is not captured. Captured PrP is then eluted and 
detected by enzyme-linked immunosorbent assay 
(ELISA) using the PrP-specific antibody POM19 
(40). 
To evaluate the sensitivity of the MPA, beads 
were incubated with 10-fold serial dilutions (10−3 
to 10−10) of a 10% (wt/vol) RML6 brain 
homogenate, and intracerebrally inoculated into 
tga20 mice overexpressing PrPC (41) 
(supplemental Table S4). Mice developed clinical 
signs after mean incubation times of 78-106 days 
(supplemental Table S4). Spongiform 
encephalopathy was confirmed in all clinically 
diseased mice by histopathological and 
immunohistochemical analysis (supplemental Fig. 
S9). Besides confirming a linear relationship 
between infectivity and MPA readings, these 
results show that peptoid-coated beads capture 
prion infectivity efficiently from RML6 and 
transmit it to tga20 mice. These data suggest that 
the MPA readings reflect the number of prion 
seeds present in a sample. 
We then mixed 1% RML6 brain homogenate 
with PTAA, POMT, pHTAA or pFTAA. These 
LCPs were chosen because they showed the 
strongest effect on infectivity in the SCEPA. All 
four compounds affected the aggregational state 
of PrPSc dose-dependently (Fig. 2D). Treatment of 
RML6 with 10 µg ml-1 PTAA, POMT and 
pFTAA significantly reduced the MPA signal (p = 
0.004, 0.015 and 0.003, respectively, 
supplemental Table S5). PTAA and POMT had 
the strongest effect at 300 and 100 µg ml-1, 
respectively, whereas pFTAA was more efficient 
at 1 and 10 µg ml-1. Already the treatment with 1 
µg ml-1 pFTAA caused a significant reduction in 
the MPA signal (p = 0.028; supplemental Table 
S5). We then pre-incubated beads with 100 µg 
ml-1 PTAA. Pretreatment of the beads had no 
effect on the capture efficiency of non-treated or 
PTAA-treated RML6 prions (supplemental Fig. 
S10 and supplemental Table S6), indicating that 
LCPs do not affect the assay by interacting 
nonspecifically with peptoid-coated paramagnetic 
beads. 
PTAA alters the conformational stability of 
PrPSc − We next investigated whether PTAA 
changes the biochemical properties of RML6 
prions by altering the conformational stability of 
PrPSc. Non-treated and PTAA-treated RML6 brain 
homogenates were incubated with increasing 
concentrations of GdnHCl for 60 min, digested 
with PK to remove soluble PrP, and analyzed by 
immunoblotting for PrPSc (42). PTAA treatment 
strongly increased the sensitivity of PrPSc to 
denaturation with GdnHCl, as reflected by a shift 
in the concentration of GdnHCl required for loss 
of PK resistance (3 M for non-treated sample, and 
2.4 and 2 M for samples exposed to 10 and 100 
µg ml-1 PTAA, respectively; Fig. 3A). 
We also incubated native and PTAA-treated 
RML6 with various concentrations of GdnHCl 
and quantified the amount of aggregated PrP by 
MPA (Fig. 3B). The inflexion point of the 
transition curve, where 50% of aggregated PrP is 
captured by the peptoids, was 1.72 M GdnHCl for 
non-treated RML6 and 0.31 M GdnHCl for 
PTAA-treated RML6. Hence PTAA-treated 
RML6 brain homogenate was more sensitive to 
GdnHCl denaturation than non-treated 
homogenate, indicating that PTAA physically 
changes the stability of PrPSc against chaotropic 
salts. 
PTAA antagonizes prion infection in 
cerebellar organotypic cultured slices − We then 
evaluated the antiprion activity of LCPs ex vivo in 
a complex cellular environment. For that, we used 
the prion organotypic slice culture assay (POSCA) 
(43,44). We used again PTAA as lead compound 
to determine the impact of LCPs onto prion 
replication and accumulation in the POSCA. 
Cerebellar organotypic cultured slices (COCS) 
were prepared from 11 days-old PrPC-
overexpressing tga20 pups and kept in culture for 
42 days (43). Cultures were analyzed for the 
presence of PrPSc at 21 days post inoculation (dpi) 
by assessing PK-resistant material on 
immunoblots (Fig. 4A). PTAA was added to the 
culture medium at 21 dpi at each medium 
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exchange (10 ng to 60 µg ml-1). Slices were 
harvested at 42 dpi, and the impact of PTAA was 
analyzed with the tools described above. 
We first compared the amounts of PrPSc 
between non-treated and PTAA-treated slices by 
PK digestion and immunoblotting (Fig. 4A). As in 
PTAA-treated RML6 brain homogenates, we 
observed a substantial, dose-dependent increase in 
PrPSc (Fig. 4A) and high-molecular weight PrP 
aggregates. Treatment with the highest PTAA 
concentration (60 µg ml-1) again lowered the 
amount of PrPSc below detectability. PPS, which 
effectively inhibited PrPSc replication in prion-
infected COCS (43), was used as control. In 
contrast to slices exposed to PTAA, PPS (0.3 µg 
ml-1) strongly reduced PrPSc when compared to 
non-treated controls. Untreated or PTAA-treated 
slices exposed to non-infected brain homogenates 
from CD1 mice, did not contain any PrPSc.  
We next investigated the effect of PTAA on 
prion replication in COCS (43). During the 
interval between 21 and 42 dpi prions were 
amplified in RML6-infected slices, as evidenced 
by an increase in infectivity from 5.7 to 7.4 log 
TCI50 g-1 (1 TCI50 unit being the dose required to 
infect 50% of PK1 culture wells; Fig. 4B). When 
slices were exposed to PTAA, a dose-dependent 
reduction in infectivity was observed. Infectivity 
was reduced by >3 log TCI50 g-1 with the highest 
PTAA concentration of 60 µg ml-1, which is >1.5 
log TCI50 g-1 below the initial infectivity at day 21 
dpi (p = 0.012, p = 0.001 and p < 0.001; 
respectively, supplemental Table S7). Treatment 
with PPS at a concentration of 0.3µg ml-1 was as 
efficient as treatment with 6 µg ml-1 PTAA and 
resulted in a reduced infectivity of >2 log TCI50 
g-1 when compared to non-treated cultures at 42 
dpi. A comparison of MPA readings (Fig. 4C) and 
SCEPA results (Fig. 4B) shows that the 
quantification of PrP aggregates in the various 
samples exactly reflected the data obtained from 
the SCEPA, again confirming a close relationship 
between the number of PrP aggregates and prion 
infectivity (Fig. 4F).  
To further validate the potency of PTAA on 
RML6-infected slice cultures, we developed a 
sandwich ELISA using antibodies POM1 for 
coating and POM19 for detection. This allowed us 
to simultaneously quantify the levels of total PrP 
(PrPC + PrPSc) and PrPSc in slice homogenates 
(Fig. 4D). Homogenates from non-treated slices 
harvested at days 21 and 42 dpi contained 
1.2 ± 1.0 and 42.9 ± 14.6 ng PrPSc per gram total 
protein. The levels of PrPSc in PTAA treated slices 
significantly declined with increasing 
concentrations of PTAA, and strongly correlated 
with the SCEPA and MPA data (Fig. 4G and H). 
A comparison of the ELISA data with the 
immunoblot indicated that the high molecular-
weight aggregates may not be detected in the 
ELISA, probably due to their resistance to 
denaturation with GdnSCN which prevents the 
exposure of buried epitopes. 
Treatment with PTAA (60 µg ml-1) 
suppressed PrPSc to values below detectability by 
ELISA (supplemental Table S8). Homogenates 
from cultures treated with 0.3 µg ml-1 PPS showed 
levels of PrPSc similar to the homogenates at day 
21 dpi and to COCS treated with PTAA at 6 µg 
ml-1. No PrPSc was detectable in uninfected 
controls. To test whether PTAA acts directly on 
PrPC, we quantified the PrPC levels in the various 
samples by subtracting the amount of PrPSc from 
total PrP (Fig. 4E). The amount of PrPC was 
unaffected in all samples except for slices treated 
with 60 µg ml-1 PTAA which showed a significant 
reduction in PrPC levels.  
PTAA treatment efficiently inhibits prion 
replication − To evaluate the efficiency of PTAA 
as a post-exposure regimen in slice cultures, we 
first generated a time-dependent standard curve 
for prion accumulation. Prion-infected slice 
cultures were harvested at days 0, 7, 19, 21, 28, 35 
and 42 dpi, and prion aggregates were analyzed 
by MPA and by sandwich ELISA after PK 
digestion. Prion aggregates and PrPSc were hardly 
detectable until 21 dpi (Fig. 5A and B), and newly 
formed PrPSc accumulated gradually thereafter 
and reached a plateau after 45 days. Prion 
accumulation was completely suppressed by 10 
µg ml-1 PTAA if treatment was initiated before 
day 21 dpi. If treatment was started at 28 dpi, a 
conspicuous inhibitory effect of PTAA was 
observed with reduction of PrP aggregates below 
the detection limit of the MPA and a strong 
decline in PrPSc when compared to non-treated 
prion-infected homogenates.  
A direct comparison of MPA and ELISA 
shows that the quantification of PrP aggregates 
with the prion-specific binding peptoids was less 
sensitive than the sandwich ELISA in this 
paradigm. Perhaps the proximal coating of PrP 
aggregates with PTAA interfered with the 
interaction between peptoids and binding sites on 
       Luminescent conjugated polymers as anti-prion compounds 
- 10 - 
PrP aggregates. Alternatively, PTAA might 
induce a structural rearrangement of the 
aggregates into larger associations that reduces the 
surface available for binding to the peptoid-coated 
beads.  
We also evaluated the levels of PrPC in 
homogenates (Fig. 5C). PrPC levels were reduced 
about two fold compared to non-treated samples 
independent from the time point at which 
treatment was started. This confirms further that 
PTAA treatment might affect prion accumulation 
by reducing the amount of PrPC, or of a transition 
intermediate on-path towards PrPSc. 
PTAA inhibits fibrillogenesis of recombinant 
PrP and affects pre-formed recombinant PrP 
fibers − We used an in vitro conversion assay to 
address the mode of action of the LCPs on prion 
replication and accumulation in a well-defined, 
simple environment. We first investigated whether 
PTAA inhibits amyloid fiber formation of the 
recombinant mouse prion protein mPrP23-231. 
Monomeric mPrP23-231 was grown under slightly 
denaturating conditions (45) in the presence of 
PTAA, and the time course of fiber formation was 
assessed by optical density measurements at 350 
nm for 48h. mPrP23-231 formed amyloid-like fibers 
by nucleation-dependent polymerization with a 
lag phase followed by an exponential growth 
phase and a plateau (Fig. 6A). The addition of 
PTAA significantly reduced the growth rate of 
fibers in a concentration-dependent manner (Fig. 
6A); incubation with 50 µg ml-1 resulted in a 
complete inhibition of fiber formation.  
We further analyzed the samples by 
negatively-stained transmission electron 
microscopy (TEM) (Fig. 6B). Electron 
micrographs (EM) of non-treated control samples 
taken after 48h showed long unbranched fibers, 
whereas fibers grown in the presence of PTAA (1-
10 µg ml-1) appeared coated with globular, 
regularly spaced PTAA aggregates. Quantitative 
analysis revealed that PTAA forms two different 
populations of aggregates with average diameters 
of 43.9 ± 6.1 nm and 16.8 ± 2.5 nm when bound 
to the fibers compared to 25.6 ± 7.4 nm and 15.4 
± 2.7 nm for the free aggregates. Both populations 
bind to the fibers with a recognizable periodicity 
(Fig. 6D, E and F), suggesting that PTAA 
interacts specifically with defined binding sites on 
the fibers. In addition, we partially observed 
coalescence of the fibers into more compact 
structures at these concentrations. Empty EM 
grids at high doses of PTAA confirmed the strong 
inhibitory effect of PTAA (Fig. 6B).  
The presence of compact fiber conglomerates 
in the samples grown in the presence of PTAA at 
concentrations between 1 and 10 µg ml-1 prompted 
us to ask whether PTAA also interacts directly 
with existing mPrP23-231 fibers. We therefore 
incubated preformed fibers with PTAA and 
analyzed their morphology by TEM. Similarly to 
the fibers grown in the presence of PTAA, fibers 
incubated with PTAA at concentrations between 1 
and 10 µg ml-1 were associated with small 
aggregates of PTAA (Fig. 6C and D). With 
increasing PTAA concentrations we observed 
progressive coating and agglomeration of fibers 
(Fig. 6C). 
We then asked whether PTAA directly 
interacts with native mPrP23-231. Native mPrP23-231 
was serially diluted and 0.2 µM PTAA was added 
to all samples. Fluorescence intensity and 
fluorescence polarization were measured 
(supplemental Fig. S11). PTAA was quenched by 
native mPrP23-231, suggesting that the probe binds 
also native PrPC or a transition intermediate on-
path towards aggregating. 
To validate that the increased PK-resistance 
of PrPSc in PTAA treated RML6 brain 
homogenates and prion-infected slice cultures can 
be ascribed to a direct interaction of PTAA on 
PrPSc independently of the sample environment, 
we investigated whether PTAA also renders 
mPrP23-231 fibers more stable to PK digestion. 
mPrP23-231 fibers were incubated with 10 µg ml-1 
PTAA prior to limited proteolysis with different 
PK concentrations and immunoblotting. Fig. 6G 
displays that PTAA directly acts on PrP as 
evidenced by a significant increase in PK 
resistance of recombinant mPrP23-231 fibers. We 
conclude that PTAA prevents prion replication 
and accumulation by acting on both PrPC and 
PrPSc aggregates in a concentration-dependent 
manner.  
 
DISCUSSION 
We had previously found that LCPs interact 
with amyloids, including PrPSc. The fluorescent 
spectra emanating from PrPSc-complexed LCPs 
allowed for differentiation of prion strains, 
suggesting a remarkable degree of steric 
specificity (28). These observations prompted us 
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to explore whether additional biophysical 
properties of prions, such as the stability of PrPSc 
aggregates and their infectiousness, may be 
affected by interactions with LCPs. The ultimate 
hope would be that these experiments might 
identify the polythiophene scaffold as a novel 
pharmacophore for the treatment of protein 
aggregation diseases.  
Indeed, not only did LCP treatment of 
infectious brain homogenates significantly reduce 
their infectivity, but also prion-infected 
organotypic slice cultures accrued less infectivity 
when exposed to LCPs. Several polythiophenes 
with diverse charged side chains and backbone 
lengths were able to reduce infectivity when 
added to prion-containing brain homogenates. The 
antiprion activity of these compounds cannot be 
attributed to the charges of their side chains, since 
anionic, cationic and zwitterionic compounds 
reduced prion infectivity to a similar extent. Also, 
neither the spacing between the side chains nor 
the rigidity of the molecules seemed to play a role 
for their antiprion activity. Based on theoretical 
considerations, the total avidity of LCPs for 
amyloids should increase with the number of low-
affinity binding sites, and therefore with the 
length of the polymers. However, very long 
polymers may have chemical properties limiting 
their interactions. Hence the activity of LCPs 
appears to be an intrinsic property of the 
polythiophene backbone itself.  
The mode of action of LCPs may involve 
more than one mechanism. When used at low 
concentrations the LCPs appear to render PrPSc 
more stable to PK digestion and to induce the 
formation of SDS-stable high-molecular-weight 
aggregates. Accordingly, PTAA transformed 
recombinant mPrP23-231 fibers into more compact 
structures. At extremely high concentrations, 
PTAA and POMT, however, significantly 
decreased the resistance of PrPSc to PK. PTAA 
also caused a left-shift in the conformational 
stability curve of PrPSc after exposure to 
increasing concentrations of the non-surfactant-
type chaotrope, GdnHCl. This concentration-
dependent behavior of the LCPs resembles the 
mechanisms reported for several surfactants 
which were assumed to affect protein aggregation 
in a two-concentration regime by either 
interacting as single molecules or in equilibrium 
with small molecule aggregates (46) and were 
demonstrated to enhance or reduce the stability 
and detectability of PK resistant PrPSc (18,47,48). 
The concentration-dependent interaction of 
surfactants with aggregated proteins may induce 
conformational versatility. Low concentrations of 
SDS and LiDs were shown to act like negatively 
charged lipid interfaces favoring the formation of 
global hydrogen bonding, thereby facilitating the 
formation of β-sheet structure and e.g. promoting 
Aβ self-assembly (49-52), whereas micellar SDS 
inhibits aggregation by enhancing α-helical 
conformational states (53). A similar mode of 
action was reported for CR which induces β-sheet 
formation and self-propagation of monomeric Aβ 
(54,55). LCPs might therefore act similarly to 
membrane mimetics that promote de novo PrP 
aggregation by converting PrP into compact 
aggregates that are more resistant to PK but less 
infectious.  
Accordingly, LCPs used at submicellar 
concentrations may prevent prion replication by 
hyperstabilization of the PrPSc conformation, 
resulting in reduced fiber frangibility – a critical 
determinant of prion infectivity (56,57) which 
controls prion propagation by fragmentation of 
fibrils and elongation of these infectious seeds 
into new fibrils (58). The higher compactness of 
LCP-treated PrPSc aggregates may reduce the 
release of infectious particles, resulting in 
decreased prion infectivity. This scenario is 
supported by studies suggesting that large 
aggregates do not correlate well with high 
infectivity (59-61). Hence LCPs can be protective 
by stabilizing fragile fibrils and perhaps even by 
incorporating pre-existing prions, and possibly 
also PrPC, into inert structures (Fig. 7). 
The PK resistance of PrPSc is widely accepted 
as surrogate marker for prion infectivity and is 
often used for the screening of novel compounds 
for the treatment of prion diseases. However, we 
found a glaring dissociation between these two 
parameters. Along with previous observations 
(48,62-68), these findings question the use of PK 
resistance as the sole screening parameter. 
Alternative methods, such as the MPA, appear to 
better reflect prion infectivity and may be better 
suited to screening for novel antiprion 
compounds.  
While the above data indicates that LCPs can 
interact with PrPSc, their antiprion effects on 
COCS suggest that LCPs may intervene at 
additional steps during the transition process of 
PrPC to PrPSc. In particular, ELISA measurements 
on COCS showed reduced levels of PrPC, 
suggesting that PTAA might deplete PrPC from 
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the cell surface or modulate PrPC levels in prion 
trafficking. This may reduce the amount of PrPC 
accessible for the transition of PrPC into PrPSc. A 
similar mode of action was reported for other 
antiprion compounds (48,69-75). This 
interpretation is supported by our finding of a 
direct interaction of PTAA with PrPC by 
performing an in vitro conversion assay with 
recombinant mPrP23-231 in the presence of PTAA 
in a cell-free environment. PTAA strongly inhibits 
the formation of mPrP23-231 fibers, supporting that 
PTAA directly interact with PrPC by either 
stabilizing the spatial conformation of PrPC or 
protecting the binding site for the template PrPSc 
molecule. Both effects may prevent efficient 
transition of PrPC into PrPSc.  
In conclusion, the interaction of the LCPs 
with PrPSc causes a structural transformation in a 
surfactant like manner mostly independent of the 
molecular character of the LCPs. The treatment 
renders PrPSc more resistant to PK digestion 
without affecting proteolysis of PrPC, and 
profoundly reduces prion infectivity. The data 
presented above link these effects to the 
hyperstabilization of PrPSc. Therefore, LCPs may 
represent a promising new class of antiprion 
compounds. The newly developed LCPs, pHTAA 
and pFTAA, were shown to cross the BBB (34) 
and may represent promising candidates for 
further exploration and for in vivo studies.  
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FIGURE LEGENDS 
 
FIGURE 1. LCPs increase the resistance of PrPSc to PK digestion in RML6 brain homogenates and 
induce the formation of higher order aggregates. A, Molecular structures of LCPs. pHTAA and pFTAA 
are homodisperse preparations of chemically defined molecules with molecular weights of 897 and 704.7 
Da, respectively. All other compounds are polydisperse preparations with average molecular weights 
ranging from 3000 to 11000 Da and number of monomers of n=11-20. B, Immunoblots of PK-digested 
RML6 samples after exposure with increasing doses of the different LCPs. On lane 1 in the blots of the 
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pHTAA and pFTAA titrations, 2 µg total protein of undigested RML6 brain homogenate was loaded as a 
control. On all other lanes 20 µg total protein of PK-digested non-infected (mock) or RML6-infected 
brain homogenate was loaded. The experiment was repeated four times with PTAA, and twice with the 
other LCPs. The immunoblot shown here is representative for the individual experiments. The anti-PrP 
antibody POM1 was used for detection. Molecular sizes are indicated in kDa. 
 
FIGURE 2. LCPs reduce prion infectivity and the amount of prion aggregates in RML6 brain 
homogenates. A, SCEPA of RML6 homogenates mixed with the different LCPs at a concentration of 300 
µg/ml. B and C, SCEPA of RML6 homogenates mixed with increasing concentrations of (B) PTAA and 
(C) pFTAA. Non-infected (mock) and RML6-infected brain homogenates were incubated with either 
PTAA or pFTAA and infectivity was determined on 17’000 cells in the SCEPA. Each data point 
represents the infectivity of one sample determined by serial tenfold dilution steps from 10-4 to 10-8 on a 
96-well plate. Data are shown as mean ± SEM. P-values represent statistical difference between 
polythiophene-treated and non-treated RML homogenates and were calculated with a Mantel-Haenszel 
Chi-square test (supplemental Table S1). Detection limit: Theoretical infectivity based on the observation 
of false positives at concentrations between 10-2 and 10-3 of non-infectious inoculum (mock). ***: p < 
0.001, **: p < 0.01, *: p < 0.05. n/a: no positive wells were observed with this sample between 
concentrations ranging from 10-3 to 10-8. ns: non significant p > 0.05. D, MPA assay was used to quantify 
prion aggregates in RML6 brain homogenates treated with increasing concentrations of PTAA, POMT, 
pHTAA or pFTAA. Each sample was analyzed in technical quadruplicates (circles) and is represented as 
the mean ± SD. All data were corrected for the negative control (mock: CD1 brain homogenate) and 
represented as relative light units normalized for RML6 prions. Statistical differences were computed to 
compare LCP-treated RML6 to the control (non-treated RML6) (supplemental Table S1) or groups of 
four concentrations of each polythiophene (supplemental Table S6).  
 
FIGURE 3. PTAA-treated RML6 prions are more sensitive to denaturation with GndHCl. A, 
Immunoblots of non-treated (upper panels) and PTAA-treated RML6 brain homogenates at different 
concentrations of GdnHCl. RML6 brain homogenate was treated with either 10 µg ml-1 (middle panel) or 
100 µg ml-1 PTAA (lower panel). Aliquots of 20 µg protein were denatured with various concentrations 
of GdnHCl, subsequently digested with PK to remove soluble PrP and loaded to the gel. The anti-PrP 
antibody POM1 was used for the detection. Molecular sizes are indicated in kDa. B, MPA of non-treated 
(open circles) and PTAA-treated RML6 brain homogenate (filled circles) after denaturation with different 
concentrations of GdnHCl. PTAA was used at a concentration of 10 µg ml-1. Each sample was analyzed 
in technical duplicates and is represented as the mean ± SD. All data were corrected for the negative 
control (CD1 brain homogenate) and represented as relative light units normalized for RML6 prions. 
Asymptotic curves were fitted to each dataset with the [GdnHCl]½ value at which 50% of the molecules 
are in a soluble fraction and 50% are in a insoluble fraction indicated by a dotted line at 1.72 M for the 
non-treated and 0.31 M for the PTAA-treated samples.  
 
FIGURE 4. PTAA affects prion replication, accumulation and neurodegeneration in slice cultures. A, 
Immunoblot from prion-infected slice cultures obtained from tga20 mice treated with different 
concentrations of PTAA. Cultures were harvested after 21 or 42 DIV and 20 µg total protein from all 
samples was digested with PK. The anti-PrP antibody POM1 was used for detection. Molecular sizes are 
indicated in kDa. The experiment was performed in biological triplicates and the immunoblot shown here 
is representative for the individual experiments. B,  SCEPA of non-infected (mock) and RML6-infected 
slice cultures after exposure to PTAA. Infectivity of non-infected cultures harvested after 21 or 42 DIV 
are shown for comparison. PPS was used as a positive control. Each diamond represents the TCI50 g-1 of 
one slice culture homogenate determined by serial tenfold dilutions from 10-4 to 10-8 on a 96-well plate. 
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Error bars indicate the mean ± SEM of biological triplicates. P-values represent the statistical differences 
between PTAA-treated and non-treated homogenates from RML6-infected slice cultures and are shown in 
supplemental Table S7. ***: p < 0.001, **: p < 0.01, *: p < 0.05. Detection limit (dashed line): 
Theoretical titer based on the observation of false positives at concentrations between 10-2 and 10-3 of 
non-infectious inoculum (CD1). n.s.: non significant. n/a: these results were not included into the 
statistical analysis. Because of mathematical complexity a statistical analysis could not be performed for 
slice cultures treated with 0.01 µg ml-1 PTAA. C, MPA of the slice culture homogenates shown in (A). 
Each dot represents the average value of technical triplicates for one slice culture homogenate. Error bars 
represent the mean ± SEM of biological triplicates. All data were corrected for the negative control 
(mock) and represented as relative light units (RLU). P-values represent the statistical differences 
between PTAA-treated and non-treated homogenates from RML6 slice cultures and are shown in 
supplemental Table S8. ***: p < 0.001. D and E, Sandwich ELISA of the same homogenates as in (A) 
analysed for PrPSc (D) and PrPC (E). Each dot represents the average value of technical duplicates for one 
slice culture homogenate. Error bars represent the mean ± SEM of biological triplicates. All data were 
normalized to protein concentration of the corresponding sample. P-values are shown in supplemental 
Table S8. The ELISA was developed with a colorimetric substrate. The detection limit of 400 pg ml-1 
(dashed line) was determined as the average background levels plus three times SD. F, Correlation 
diagram to show the relationship between the MPA and SCEPA data presented in (B) and (C). G, 
Correlation diagram to show the relationship between the SCEPA and ELISA data presented in (B) and 
(D). H, Correlation diagram to show the relationship between the MPA and ELISA data presented in (C) 
and (D). 
 
FIGURE 5. PTAA inhibits prion accumulation in RML6-infected slice cultures from different time 
points. A, MPA of homogenates from RML6 infected slices harvested at days 7, 19, 21, 28, 35 and 42 
DIV. PTAA was administered at a concentration of 10 µg ml-1 at the time of medium change freshly into 
the medium from days 7, 19, 21, 28 or 35 DIV. Slice cultures were harvested at 42 DIV and analyzed for 
PrP aggregates. Each dot represents the average value of technical triplicates for one slice culture 
homogenate. Error bars represent the mean ± SEM of biological duplicates. All data were corrected for 
non-infectious brain homogenates obtained from CD1 mice as negative control (mock) and represented as 
the ratio between relative light units (RLU) and protein concentration for each sample. P-values are 
shown in supplemental Table S9. B, Sandwich ELISA of the same homogenates as in (A) analysed for 
PrPSc. The data are represented as biological triplicates. The signal for the negative control (mock) is 
shown as single replica. C. Sandwich ELISA of the same homogenates as in (A) analysed for PrPC. The 
ELISA was developed by chemiluminescence. The detection limit of 600 pg ml-1 (dashed line) was 
determined as the mean background levels plus three times SD. 
 
FIGURE 6. Effect of PTAA on mPrP23-231 fiber formation and preformed fibers. A, Time course of 
mPrP23-231 fiber formation grown in the absence (filled circles) and presence of PTAA at different 
concentrations of 5 µg ml-1 (open circles), 10 µg ml-1 (filled squares), 25 µg ml-1 (open squares) and 50 µg 
ml-1 (filled diamonds) monitored by measuring the OD350 over a period of 48h. Error bars represent the 
SD of technical triplicate measurements. B, TEMs taken after 48h of control fibers grown in the absence 
of PTAA and in the presence of different concentrations of PTAA. C, TEM of preformed mPrP23-231 fibers 
incubated with different concentrations of PTAA. The electron micrograph in the right lower corner 
displays fibers incubated with 1 µg ml-1 PTAA at higher magnification. D, TEM of fibers recorded from 
another independent experiment grown in the presence of 10 µg ml-1 PTAA (upper panel) and of 
preformed mPrP23-231 fibrils mixed with 1 µg ml-1 PTAA (lower panel). E, PTAA formed two different 
populations of small aggregates at concentrations between 1 and 10 µg ml-1 which were associated at the 
fibers with mean diameters of 43.9 ± 6.1 nm for population 1 (P1) and 16.8 ± 2.5 nm for population 2 
       Luminescent conjugated polymers as anti-prion compounds 
- 19 - 
(P2). Free aggregates had mean diameters of 25.6 ± 7.4 nm for population 1 (FP1) and 15.4 ± 2.7 nm for 
population 2 (FP2). Data are represented as the mean ± SD. F, PTAA aggregates were located on the 
fibers in a highly periodic manner with distances of 42.2 ±12.5 nm for population 1 and 36.3 ± 8.6 nm for 
population 2. Data are represented as the mean ± SD. G, PTAA increases the resistance of mPrP23-231 
fibers to PK digestion. Aliquots of mPrP23-231 fibers were incubated with 10 µg ml-1 PTAA prior to 
proteolysis with increasing concentrations of PK. Lane 1 contains non-digested mPrP23-231 fibers. Scale 
bar: 100 nm. 
 
FIGURE 7. Model for the antiprion activity of the LCPs. A, In the prion model PrPC is in a reversible 
thermodynamic equilibrium with PrP*, which further aggregates into amyloid fibrils, PrPSc. When the 
fibrils reach a critical length, the fibril becomes more fragile and fragmentation occurs. The newly formed 
ends of the fibril fragments are new nucleation sites for further fibril growth. B, The antiprion activity of 
the LCPs seems to be based on interactions with PrPSc aggregates, possibly increasing their compactness. 
LCP coated fibrils further embed preexisting prions and even PrPC. The higher compactness of the PTAA 
treated aggregates ultimately cause less fragmentation into infectious particles necessary for further prion 
replication. 
 
 
 
 
 
 







